Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study.

The acute phase response

1994 • 2,927 citations

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

1987 • 2,769 citations

Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

1987 • 1,224 citations

Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2

1994 • 991 citations

Interleukin-6 and Its Receptor: A Paradigm for Cytokines

1992 • 889 citations

IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice.

1989 • 578 citations

Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.

1992 • 394 citations

A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).

1983 • 360 citations

TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER

1989 • 337 citations

Spontaneous Regression of Cancer

1956 • 320 citations

Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression.

1993 • 233 citations

Antitumor activity of recombinant interleukin 6 in mice.

1990 • 230 citations

Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.

1987 • 211 citations

Direct evidence to support the immunosurveillance concept in a human regressive melanoma.

1994 • 171 citations

Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression.

1992 • 168 citations

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.

1993 • 147 citations

Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.

1989 • 134 citations

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.

1994 • 131 citations

Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.

1995 • 127 citations

In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation

1989 • 122 citations

Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients

1994 • 121 citations

Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice

1993 • 80 citations

Prognosis After Initial Recurrence of Cutaneous Melanoma

1991 • 66 citations

Effective chemotherapy for melanoma after treatment with interleukin-2

1992 • 57 citations

Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.

1991 • 50 citations

Lack of correlation between peripheral blood lymphokine-activated killer (lak) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2

1989 • 47 citations

Current status of Interleukin-2 therapy in cancer

1992 • 43 citations

Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.

1990 • 32 citations

IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters.

1992 • 22 citations

Interleukin 2 therapy in cancer: identification of responders

1992 • 21 citations

In vitro predictors of clinical response in patients receiving interleukin-2-based immunotherapy

1993 • 21 citations

Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with decarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response

1992 • 15 citations

[Analysis of changes in serum levels of TNF, IL-1 and IL-6 during administration of IL-2. Correlation with clinical response to treatment].

1992 • 8 citations

Generation of monoclonal antibodies against HILDA/LIF and their use in the quantitative assay of the cytokine

1993 • 4 citations